argenex (NASDAQ:ARGX) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft

argenex (NASDAQ:ARGX) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Marketbeat.com reports.

Several other equities analysts have also recently commented on ARGX. Baird R W upgraded shares of argenex from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 13th. Citigroup reissued a “buy” rating on shares of argenex in a research report on Wednesday, May 21st. Wedbush reissued an “outperform” rating and set a $715.00 target price on shares of argenex in a research report on Tuesday, June 24th. Guggenheim lowered their target price on shares of argenex from $1,100.00 to $1,065.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Finally, Oppenheimer increased their target price on shares of argenex from $704.00 to $708.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Nineteen equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $728.06.

argenex Stock Up 3.1%

Shares of NASDAQ:ARGX opened at $555.19 on Tuesday. The company’s fifty day moving average is $570.86 and its two-hundred day moving average is $602.95. argenex has a 12-month low of $457.42 and a 12-month high of $678.21. The company has a market cap of $33.90 billion, a P/E ratio of 34.25, a price-to-earnings-growth ratio of 0.99 and a beta of 0.37.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $748.34 million. Equities research analysts anticipate that argenex will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenex

Hedge funds have recently made changes to their positions in the stock. GeoWealth Management LLC lifted its stake in shares of argenex by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after buying an additional 18 shares during the period. Rakuten Securities Inc. raised its position in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company’s stock worth $36,000 after purchasing an additional 22 shares in the last quarter. WPG Advisers LLC acquired a new position in argenex in the first quarter worth about $37,000. FIL Ltd acquired a new position in argenex in the fourth quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in argenex in the fourth quarter worth about $38,000. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.